Project: Natural human monoclonal antibodies against Fibroblast Activation Protein to treat multiple myeloma

Natural human antibodies against FAP will be developed as a medication to treat multiple myeloma. These antibodies will be discovered in rare multiple myeloma patients experiencing stable disease or even spontaneous remissions without treatment, and then recombinantly produced with Mabimmune’s RTM™ technology. Finally, an IND-ready data package will be delivered including proof of efficacy in two unique multiple myeloma mouse models that mimic the human disease.

Acronym	MM-HUMAB (Reference Number: 9535)
Duration	01/07/2015 - 01/07/2017
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
21001	Mabimmune	Coordinator	Switzerland
21002	University of Oslo	Partner	Norway